Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report), Xenon (XENE – Research Report) and BioLife Solutions (BLFS – Research Report).
BioNTech SE (BNTX)
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE today and set a price target of $101.00. The company’s shares closed last Thursday at $92.06.
According to TipRanks.com, Merle is a 1-star analyst with an average return of
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $112.70, representing a 24.9% upside. In a report issued on May 6, Jefferies also maintained a Hold rating on the stock with a $100.00 price target.
See today’s best-performing stocks on TipRanks >>
Xenon (XENE)
Wedbush analyst Laura Chico maintained a Buy rating on Xenon today and set a price target of $50.00. The company’s shares closed last Thursday at $42.49.
According to TipRanks.com, Chico is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $58.50 average price target, representing a 36.3% upside. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $55.00 price target.
BioLife Solutions (BLFS)
Northland Securities analyst Carl Byrnes maintained a Buy rating on BioLife Solutions today and set a price target of $26.00. The company’s shares closed last Thursday at $18.01.
According to TipRanks.com, Byrnes is ranked 0 out of 5 stars with an average return of
BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $23.60, representing a 32.4% upside. In a report released yesterday, Craig-Hallum also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNTX:
